Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs) Figure 3 | Natural and imatinib-induced immunosurveillance.

Published byJohnathan Haynes Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs) Figure 3 | Natural and imatinib-induced immunosurveillance."— Presentation transcript:

1 Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs)
Figure 3 | Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs). a | Natural immunosurveillance in GIST. GIST contain regulatory T (TREG) cells, as well as CD4+ type 1 helper T cells (TH1), CD8+ type 1 cytotoxic T cells (TC1 cells) located in the tumour nests surrounded by CD56bright CD16dim/− natural killer (NK) cells. b | Effects of imatinib on the tumour microenvironment. Imatinib promotes a loss of MHC class I molecules, which might reflect the T-cell-mediated elimination of MHC-I-positive tumour cells and hence an example of 'immunoediting'. Imatinib can reduce intratumoural TREG-cell numbers and cause a relocation of NK cells from the stroma to tumour foci, leading to a marked increase of the NK:TREG cell ratio in situ. The imatinib-induced increase of the NK:TREG-cell ratio is more pronounced in the subset of GIST harbouring an exon 11 KIT mutation83. Kroemer, G. et al. (2016) Immunological off-target effects of imatinib Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs) Figure 3 | Natural and imatinib-induced immunosurveillance."

Similar presentations

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Figure 1 Key elements of cancer-related inflammation

Figure 1 Key elements of cancer-related inflammation
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 1 Radiation-induced effects on tumour cells

Figure 1 Radiation-induced effects on tumour cells
Figure 2 Immune-escape mechanisms of CTCs in the peripheral blood

Figure 2 Immune-escape mechanisms of CTCs in the peripheral blood
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 2 Neoantigen presentation in the tumour microenvironment
Figure 1 Four nodes to target when inducing anti-tumour immunity

Figure 1 Four nodes to target when inducing anti-tumour immunity
Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Monitoring clonal evolution using liquid biopsies
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Similar presentations

Ads by Google